Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic
activity, have recently attracted attention as potential anticancer therapeutics. While NK cells …

In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …

Adenosine receptors (ARs) are widely acknowledged pharmacological targets yet are still
underutilized in clinical practice. Their ubiquitous distribution in almost all cells and tissues …

Multicomponent reactions (MCRs) have emerged as a powerful strategy in synthetic organic
chemistry due to their widespread applications in drug discovery and development. MCRs …

Adenosine, an immunosuppressive metabolite, is produced by adenosine triphosphate
(ATP) released from dying or stressed cells and is found at high levels in the tumor …

The modulation of the A2B adenosine receptor is a promising strategy in cancer (immuno)
therapy, with A2BAR antagonists emerging as immune checkpoint inhibitors. Herein, we …

Sepsis is an unsolved clinical condition with a substantial mortality rate in the hospital.
Despite decades of research, no effective treatments for sepsis exists. The role of adenosine …

The suppressive tumour microenvironment significantly hinders the efficacy of
immunotherapy in treating solid tumors. In this context, stromal cells, such as tumour …

Adenosine receptors, particularly A2BAR, are gaining attention for their role in pathological
conditions such as cancer immunotherapy, prompting the exploration for promising …

Antagonists of the A 2B adenosine receptor have recently emerged as targeted anticancer
agents and immune checkpoint inhibitors within the realm of cancer immunotherapy. This …